Ravasio, R., Tiseo, M., Pradelli, L., Bellone, M., Gervasi, A. and Coffani, M. 2019. Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Global and Regional Health Technology Assessment. 6, 1 (Jun. 2019). DOI:https://doi.org/10.33393/grhta.2019.462.